Roche plots route to EMA approval for DMD gene therapy
To read the full story, subscribe or sign in. April 17, 2026 By Nuala Moran No Comments Roche…
Still no scare for Ohtuvayre: Roche IL-33 COPD data mixed
The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled…
Jazz-Roche lung cancer combo approved by FDA
The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung…
Roche follows other pharmas, committing $50B in US investment
Roche AG has become the latest pharmaceutical company to respond to the Trump administration’s threat to impose tariffs,…
MASH dash speeds up as Roche acquires 89bio for up to $3.5B
The dash for MASH is gaining momentum, with Roche AG acquiring 89bio Inc. and its phase III FGF21…
CERAN wrap: Roche phase III BC win seals thesis, boosts Olema
Roche AG’s Genentech unit landed another clinical victory with giredestrant that provided a major stock boost for competitor…
Roche gains US, EU nod for whooping cough test as cases surge
Roche AG received regulatory clearance from the U.S. and European authorities for a new diagnostic test that detects…
Roche secures CE mark for vaginitis diagnostic test
Roche AG received CE mark for its cobas Bacterial Vaginosis/Candida Vaginitis assay, which will help to improve accuracy…